Cargando…

Synergistic effects of olaparib combined with ERCC1 on the sensitivity of cisplatin in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is a common malignant tumor. ERCC excision repair 1 endonuclease non-catalytic subunit (ERCC1) is a key mediator of nucleotide excision repair. The present study aimed to explore the synergistic effects of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Kejie, Ni, Xiaoyan, Lv, Shanmei, Zhou, Guozhong, He, Honger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967929/ https://www.ncbi.nlm.nih.gov/pubmed/33747222 http://dx.doi.org/10.3892/ol.2021.12626

Ejemplares similares

Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells
por: Gao, Jianwen, et al.
Publicado: (2021)

Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149
por: He, Yuwen, et al.
Publicado: (2020)

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
por: Whicker, Margaret E., et al.
Publicado: (2016)

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
por: Yarchoan, Mark, et al.
Publicado: (2017)

Inhibiting the MCM8‐9 complex selectively sensitizes cancer cells to cisplatin and olaparib
por: Morii, Issay, et al.
Publicado: (2019)

Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines
por: Ávila-Arroyo, Sonia, et al.
Publicado: (2015)

The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients
por: Obiedat, Hadeel, et al.
Publicado: (2018)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis
por: Wu, Yan, et al.
Publicado: (2022)

MiR-192-5p reverses cisplatin resistance by targeting ERCC3 and ERCC4 in SGC7901/DDP cells
por: Xie, Xiaoque, et al.
Publicado: (2019)

ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer
por: Han, Ji-Youn, et al.
Publicado: (2017)

The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC
por: Cai, Yang, et al.
Publicado: (2015)

High-Mobility Group Box 1 (HMGB1) Promotes Angiogenesis and Tumor Migration by Regulating Hypoxia-Inducible Factor 1 (HIF-1α) Expression via the Phosphatidylinositol 3-Kinase (PI3K)/AKT Signaling Pathway in Breast Cancer Cells
por: He, Honger, et al.
Publicado: (2019)

ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine
por: Ulker, Mehmet, et al.
Publicado: (2015)

Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property
por: Prasad, Chandra Bhushan, et al.
Publicado: (2017)

The Association of ERCC1 and ERCC5 Polymorphisms with Lung Cancer Risk in Han Chinese
por: Lan, Xueling, et al.
Publicado: (2022)

Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression
por: Usanova, Svetlana, et al.
Publicado: (2010)

Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers
por: Jin, Yonglong, et al.
Publicado: (2020)

The combination of olaparib and camptothecin for effective radiosensitization
por: Miura, Katsutoshi, et al.
Publicado: (2012)

Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients
por: Nicoś, Marcin, et al.
Publicado: (2020)

Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells
por: Arora, Sanjeevani, et al.
Publicado: (2016)

MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
por: Yi, Jingyan, et al.
Publicado: (2019)

Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report
por: Lai, Yi-Hsuan, et al.
Publicado: (2022)

ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines
por: Weaver, David A, et al.
Publicado: (2005)

Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality
por: Jiang, Yanyan, et al.
Publicado: (2016)

Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2022)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females
por: Yin, Zhihua, et al.
Publicado: (2009)

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells
por: Wang, Jing, et al.
Publicado: (2019)

Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer
por: Rose, Maimon C., et al.
Publicado: (2014)

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010)

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
por: Mahdi, Haider, et al.
Publicado: (2021)

The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells
por: Guo, Jiwei, et al.
Publicado: (2018)

Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in a Chinese population
por: Ni, Min, et al.
Publicado: (2014)

Outcome Definition Influences the Relationship between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients
por: Zazuli, Zulfan, et al.
Publicado: (2019)

Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells
por: Chen, Hai-Ming, et al.
Publicado: (2018)

Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
por: Moutafi, Myrto, et al.
Publicado: (2023)

ERCC1 and ERCC2 Haplotype Modulates Induced BPDE-DNA Adducts in Primary Cultured Lymphocytes
por: Lu, Xiaobo, et al.
Publicado: (2013)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2015)

Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
por: Varanda, Ana Beatriz, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e2vbksjs2svhv8tfdrgfoq6hsq